Establishment of a new three-dimensional dose evaluation method considering variable relative biological effectiveness and dose fractionation in proton therapy combined with high-dose-rate brachytherapy

Conclusions: Our dose evaluation method can evaluate the EQD2LQLconsidering RBE changes in the dose distribution.
Source: Journal of Medical Physics - Category: Physics Authors: Source Type: research

Related Links:

Abstract Seeking a second medical advice as a medical practitioner is a frequent situation that should be facilitated to best suit patients' expectations, while maintaining medical confidentiality. The patient and his relatives need to be involved with diagnostic and therapeutic procedures. The radiation oncologist should accept and help a patient who seeks a second advice, and patients will always appreciate when the physician helps them to seek such an advice. Examples that each practitioner should know include tertiary centers tumor boards, centers with access to innovation or clinical research, or with special...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Despite the increasing popularity of advanced external beam radiotherapy techniques such as proton therapy and radiosurgery, radioactive plaque brachytherapy remains the dominant vision-preserving treatment for intraocular tumors [1,2]. Nowadays, the most widely used eye brachytherapy plaques are gold shells with embedded seeds of a low-energy γ emitting radionuclide such as I-125, Pd-103, and Cs-131 [1–3]. Prefabricated solid silver or platinum shells encapsulating a pure b-emitter such as Ru-106/Rh-106 and Sr-90/Y-90 are also widely used for ocular tumors
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
CONCLUSION: Dose escalation with hypofractionated proton boost was as effective as reported with high dose-rate brachytherapy boost, and the GU and GI toxicity profile was very similar. The proton boost was also appropriate for patients with larger prostate volume, higher T-stage, and high-risk disease encompassing elective regional node photon therapy. PMID: 31431382 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Purpose of review To discuss alternative strategies for multimodal treatments of nonmetastatic bladder–prostate rhabdomyosarcoma performed with the aim of preserving organ function. Recent findings Bladder–prostate rhabdomyosarcomas are seldom fully resectable at presentation or after induction chemotherapy, and extensive resection might not improve survival. When an organ-sparing approach is pursued, radiotherapy might be unavoidable to achieve reliable local control of the disease. Benefits of preoperative vs. postoperative radiotherapy have yet to be investigated. Multimodal treatments may often result ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PAEDIATRIC URO-ONCOLOGY: Edited by Manuela P. Hiess Source Type: research
Ocular proton therapy (OPT) is considered the elective treatment for different kinds of highly malignant intraocular tumor. Uveal, iris and conjunctival melanomas, ocular hemangioma and retinoblastomas are amongst the lesions typically treated with OPT, particularly if target thickness prevents the applicability of other treatment modalities such as brachytherapy [1 –4]. A remarkable local control rate (well over 90%) was reported over the years by several institutions with over 28.000 patients treated worldwide [1,5,6], even though concomitant counter-effects, such as radiation induced damage to the lacrimal gland, ...
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
The U.S. Trade Representative has approved a request from radiation oncology...Read more on AuntMinnie.comRelated Reading: Varian gets China OK for Halcyon system Varian launches Bravos brachytherapy system Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Radiation oncology firm Varian Medical Systems has received clearance for its...Read more on AuntMinnie.comRelated Reading: Varian launches Bravos brachytherapy system Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona Varian signs educational partner in India
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Radiation oncology firm Varian Medical Systems has introduced Bravos, a new...Read more on AuntMinnie.comRelated Reading: Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona Varian signs educational partner in India Varian makes changes at 2 divisions
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Authors: Podder TK, Fredman ET, Ellis RJ Abstract Major categories of radiotherapy (RT) for prostate cancer (CaP) treatment are: (1) external beam RT (EBRT), and (2) brachytherapy (BT). EBRT are performed using different techniques like three-dimensional conformal RT (3D-CRT), intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated proton therapy (IMPT), etc., using a variety of radiation delivery machines, such as a linear accelerator (Linac), Cyberknife robotic system, Gamma knife, Tomotherapy a...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Eye-preservation using brachytherapy (BT) and proton therapy (PT) are commonly used as primary treatments for uveal melanomas (UM). Choice of modality generally depends on local availability rather than direct assessment of the two techniques. We conducted a comparative dose planning study, estimating biologically effective doses (BED) to the tumour, macula and optic nerve head (ONH).
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Source Type: research
More News: Brachytherapy | Physics | Proton Therapy | Study